Quick Answer
HOOKIPA Pharma Inc. reported R&D Expense of $68.51 million for fiscal year 2024.
HOOKIPA Pharma Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $68.51M | -20.7% |
| 2023 | $86.42M | +25.9% |
| 2022 | $68.64M | -17.1% |
| 2021 | $82.85M | +51.2% |
| 2020 | $54.79M | +18.3% |
| 2019 | $46.31M | +110.8% |
| 2018 | $21.96M | +124.8% |
| 2017 | $9.77M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| March 31, 2025 | $12.86M | -36.2% | -17.4% |
| September 30, 2024 | $15.56M | -36.8% | -21.2% |
| June 30, 2024 | $19.75M | +0.2% | -2.1% |
| March 31, 2024 | $20.17M | -3.6% | -18.1% |
| September 30, 2023 | $24.62M | +34.7% | +25.0% |
| June 30, 2023 | $19.71M | +22.0% | -5.9% |
| March 31, 2023 | $20.93M | +25.9% | +14.5% |
| September 30, 2022 | $18.29M | -11.7% | +13.2% |
- HOOKIPA Pharma Inc. showed a decrease of -20.7% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2024 period, HOOKIPA Pharma Inc.’s r&d expense has grown by 601.1% (from $9.77 million to $68.51 million).
- The most recent figure is from HOOKIPA Pharma Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on February 28, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: